Tvardi Share Price

Tvardi Share Price

NASDAQ: TVRD | Micro Cap | Healthcare
$1.00
-$0.02 (-1.7%) Last updated on 21 Nov, 2026 | 00:12 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • About
  • Price history
  • FAQs

Tvardi Stock Performance

Open
$0.92
Prev. Close
$1.01
Circuit Range
N/A
Day Range
$0.92 - $1.00
Year Range
$0.79 - $5.66
Volume
2,218
Average Traded
$0.93

Tvardi Share Price Today

As of 21 November 2026, Tvardi Therapeutics, Inc.'s share price is $1.00. The stock opened at $0.92, compared to its previous close of $1.01. During today's trading session, Tvardi Therapeutics, Inc.'s share price traded between $0.92 and $1.00, with an average price of $0.96. Over the past 52 weeks, the stock has recorded a high of $5.66 and a low of $0.79. In terms of performance, Tvardi Therapeutics, Inc.'s share price has declined by 70.57% over the last six months and is down 75.81% on a year-on-year basis.

Tvardi Share Price Chart

Line chart of the Tvardi price trend over the selected period. The price fell overall, ranging from 0.92 to 1.00, ending at 1.00.
$0.92$1.00
L
Show Current Price
H

Tvardi Stock Fundamentals & Key Indicators

Market Cap
$7.40M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-2.00
Revenue (TTM)
$0.00
Return On Equity (TTM)
-172.49%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
15.93%

Tvardi Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$7.28-$6.80-$6.46-$6.12
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A6.59%5.00%5.26%

Tvardi Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$18.21
Net Profit MarginN/A
Income ChangeN/A

Tvardi Balance Sheet

All figures in USD Million

Particulars2025
Non Current Assets0.54
Current Assets31.54
Total Assets32.07
Non Current Liabilities0.09
Current Liabilities11.04
Total Liabilities11.13
Shareholders' Equity20.95

Tvardi Cash Flow

Annually

All figures in USD Million

Particulars2025
Operating-23.5
Investing-10.08
Financing22.7

About Tvardi

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Tvardi Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$0.83
$1.00
+23.24%
Oct 2026
$1.22
$0.81
-34.76%
Sep 2026
$1.81
$1.24
-32.24%
Aug 2026
$2.06
$1.83
-13.27%
Jul 2026
$1.86
$2.11
+9.61%
Jun 2026
$3.33
$1.93
-43.22%
May 2026
$3.13
$3.39
+8.31%
Apr 2026
$3.11
$3.13
-1.57%
Mar 2026
$4.11
$3.18
-20.10%
Feb 2026
$3.93
$3.98
+0.76%
Jan 2026
$4.26
$3.95
-8.35%
Dec 2025
$4.08
$4.31
+4.48%

Tvardi Share Price FAQs